Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.

Financially, Verve has a market cap of $475mn, cash balance of $540mn, and a cash runway of 7-8 quarters. Find out my ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 25.48% ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today ...

EXCLUSIVE: Academy Award-winning NYC studio Believe Entertainment Group has signed with Verve for representation. The news ...

EXCLUSIVE: Verve is expanding its talent and literary divisions with the hires of Jennifer Trofa as a TV Literary Agent and ...

H.C. Wainwright lowered the firm’s price target on Verve Therapeutics (VERV) to $14 from $15 and keeps a Buy rating on the shares after the company announced that it has dosed seven patients ...

When Ford unveiled the concept version of their new B-class mini car at the Frankfurt Motor Show it was called the Verve. The production version of this car, which is expected to debut next March ...

Sporty and coupe-like, the Verve Concept notchback provides a very clear vision about Ford's future small car design direction. The three-door hatchback Verve Concept was a star of the recent ...